Autres langues Alligator Bioscience AB London S.E.

Actions

0RK9

SE0024173637

Recherche biotechnologique et médicale

Marché Fermé - London S.E. 12:55:48 18/12/2025			Varia. 5j.	Varia. 1 janv.
0,3209 ^SEK	-99,99%		+1 313,66%	-0,28%

07/09	Retrait des alertes concernant l'augmentation de capital d'Alligator Bioscience	RE
01/09	Alligator Bioscience se négocie aujourd'hui sur le Nasdaq Stockholm hors droit de souscription dans le cadre de son augmentation de capital	FW

Autres langues

07/09	Alerts on Alligator Bioscience conducting rights issue withdrawn
31/08	Alligator Bioscience publishes prospectus in connection with rights issue
28/08	Alligator Bioscience (Q2 2026 Review): The HLX22 waiting game
26/08	Bulletin from the extraordinary general meeting in Alligator Bioscience AB
26/08	Alligator Bioscience AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
26/08	Alligator Bioscience AB reports financial results for the period 1 January – 30 June 2026 and provides a business update
20/08	Alligator Bioscience : Invitation to Alligator Bioscience's earnings call on 26 August 2026
20/08	Invitation to Alligator Bioscience’s earnings call on 26 August 2026
23/07	Notice of extraordinary general meeting in Alligator Bioscience AB
23/07	Alligator discontinues independent development of mitazalimab for a strategic refocus on the HLX22 project, announces a rights issue of units of approximately SEK 125.6 million and raises bridge loans
02/07	Alligator announces first patient dosed in investigator-initiated study of intratumoral mitazalimab in early-stage breast cancer
02/07	Alligator Bioscience Doses First Patient In Investigator-Initiated Study Of Intratumoral Mitazalimab In Early-Stage Breast Cancer
08/06	Alligator Bioscience comments on Henlius update on global phase 3 trial with HLX22
08/06	Alligator Bioscience Comments on Henlius Update on Global Phase 3 Trial with Hlx22
22/05	Alligator Bioscience comments on Henlius update on long-term follow-up data for HLX22
08/05	Alligator Bioscience (Q1 2026 Review): Pragmatic Path to Phase III
06/05	Bulletin from the annual general meeting in Alligator Bioscience AB on 6 May 2026
06/05	Alligator Bioscience AB Elects New Board Members
05/05	Alligator Bioscience AB Reports Earnings Results for the First Quarter Ended March 31, 2026
05/05	Alligator Bioscience Q1 net loss SEK 1.4 million
05/05	Alligator Bioscience AB reports financial results for the period 1 January – 31 March 2026 and provides a business update
28/04	Invitation to Alligator Bioscience's Earnings Call on 5 May 2026
28/04	Invitation to Alligator Bioscience’s earnings call on 5 May 2026
23/04	Alligator Bioscience comments on Henlius presentation of HLX49 preclinical data at AACR 2026
23/04	Alligator Bioscience Announces Preclinical Data Presentation of Hlx49 Antibody?Drug Conjugate